



Charles A. Sammons Cancer Center

Radiation Oncology

DOCKETED  
USNRC

R. Pickett Scruggs, M.D.  
Director

November 6, 2008 (4:30pm)

B. Scott Cheek, M.D.  
Neil M. Senzer, M.D.  
Barry N. Wilcox, M.D.

Annette L. Vietti-Cook  
Secretary of the Commission  
U.S. Nuclear Regulatory Commission  
Washington, DC 20555-0001

OFFICE OF SECRETARY  
RULEMAKINGS AND  
ADJUDICATIONS STAFF

ATTN: Rulemakings and Adjudications Staff

Re: Comments on Proposed Rule for Medical Use of Byproduct Material—  
Amendments/Medical Event Definitions (RIN 3150-A126, NRC-2008-0071) [See 73 FR  
45635 (August 6, 2008)]

Dear Ms. Vietti-Cook:

*I am a radiation oncologist at Baylor University Medical Center who regularly performs brachytherapy. I have performed over 300 I-125 implants prostate implants over the past 10 years. My partners and I also perform regular HDR breast brachytherapy and GYN brachytherapy. I am concerned that the U.S. Nuclear Regulatory Commission's (NRC's) proposed modifications to 10 CFR 35.40 and 35.3045 to establish separate medical event criteria and written directive requirements for permanent implant brachytherapy would result in inappropriately categorizing some medically acceptable implants as "medical events" (ME's).*

First, I would like to discuss the proposed rule language for § 35.40(b)(6) and § 35.3045(a)(2) is unrealistic in that it does not take into account clinical practice realities. While I don't practice real time dosimetry for my prostate implantations, I trained in this method and therefore know how this rule change could adversely affect practitioners that do use it. Many authorized users (AUs) perform real-time, adaptive, interactive planning, whereby the written directive and the source strength to be implanted are based on the actual volume dynamically determined during the procedure rather than based on the pre-implant volume.

Real-time planning is a more accurate method of implantation. It allows the physician to take into account any alterations in the organ volume and shape that occur between the time of the pre-plan and the implant procedure and therefore represents the actual organ volume and implant situation. For those performing real-time adaptive planning implantation, the total source strength to be implanted is determined intraoperatively during the implantation procedure and not pre-implant. Further, even those performing permanent brachytherapy using preplanned techniques will often modify their plan if

intraoperatively they find major discrepancies in the gland or organ volume from the volumes determined during the preplan.

I support ASTRO's suggested revisions to the proposed regulations. I believe this modification will clarify that the source strength implanted as stated in the WD refers to the source strength implanted after administration but before the patient leaves the post-treatment recovery area.

Second, I would like to discuss the definition of "treatment site" described in § 35.2 as "the anatomical description of the tissue intended to receive a radiation dose, as described in a written directive" leads to some ambiguity regarding the exact volume that "treatment site" refers to in § 35.3045(a)(2)(ii). There are various standard volumes already defined in radiation oncology, including the gross tumor volume, which is the volume that contains tumor. Two other margins are added to the gross tumor volume during the brachytherapy planning process. One margin is added to account for the subclinical spread of tumor, which is termed the "clinical target volume," and a second margin is added to account for uncertainties in source positioning, tumor boundaries, isodose constrictions, etc., which is termed the "planning target volume."

These expansion margins are not constant but change for different clinical situations. Radiation oncologists use a larger margin if there is high degree of uncertainty and/or if there are no adjacent critical structures. Conversely, the margins are smaller if the boundary is distinct and/or if there are adjacent critical structures.


I believe that the proposed regulations cross into clinical decision-making by specifying margin parameters and the source strength to be placed in the margin. The NRC will be interfering into medical judgment if it dictates the amount of source strength the authorized user can place in the margins. Using the definition found at § 35.2 of "treatment site" as "the anatomical description of the tissue intended to receive a radiation dose, as described in a written directive" raises ambiguities in terms of the proposed medical event reports and notifications as it is unclear whether the "treatment site" refers to the gross tumor volume or includes the margins in the clinical target volume or those in the planning target volume.

I support ASTRO's recommended changes to the definition of "treatment site" at § 35.2 be revised to reflect the distinct clinical areas - gross tumor, the clinical target volume, plus a variable planning target volume. Further, by following ASTRO's suggested alternative language, section § 35.3045 (a)(2)(iii) of the proposed rule would become superfluous and therefore could be eliminated.

I believe that these suggested modifications to the proposed rule language are necessary because in the normal course of some medically acceptable brachytherapy implant procedures, a few seeds may come to rest beyond 3 cm (1.2 in) from the outside boundary of the treatment site. Since I perform brachytherapy using many seeds of low activity this does not usually adversely affect the implant but might be stray from the definition of "treatment site" as outlined above.

I hope you consider what a practitioner deals with on a day to day basis. Thank you for giving me this opportunity to provide comments on the NRC's proposed rule changes to 10 CFR 35.40 and 35.3045 related to medical events in permanent implant brachytherapy. Please contact me at 214 370-1400 if you have any questions.

Sincerely,



Barry Wilcox, MD